Next Generation
Immune Modulation

South San Francisco, California

Engineering the Future

About Sundance Bio

Sundance Biosciences is developing three oral therapies targeting TYK2, an enzyme that plays an important role in regulating the immune system. Our two most advanced programs, one of which is brain-penetrant and one of which is peripherally-restricted, have completed Phase 1 clinical trials and demonstrated exceptional target engagement profiles.

Scientist looking through a microscope in a laboratory

Close-up abstract representation of a molecular or DNA structure composed of colorful spheres.

Our Programs

Program	Therapeutic Area	Discovery Lead Op IND-Enabling Phase 1 Phase 2
SUN-627 Brain-penetrant TYK2 inhibitor	Multiple sclerosis	Start of Phase 1
SUN-907 Brain-penetrant TYK2 inhibitor	Neuroinflammatory conditions	IND-Enabling
SUN-111 Peripheral TYK2 inhibitor	Peripheral inflammatory conditions	In Phase 1

Program

Therapeutic Area

Discovery

Lead Op

IND-Enabling

Phase 1

Phase 2

SUN-627

Brain-penetrant TYK2 inhibitor

Multiple sclerosis

SUN-907

Brain-penetrant TYK2 inhibitor

Neuroinflammatory conditions

SUN-111

Peripheral TYK2 inhibitor

Peripheral inflammatory conditions

Our Team

We are an experienced team of scientists and operators dedicated to the development of TYK2 therapies designed to meaningfully impact the lives of patients suffering from immunology disorders.